JP2023547883A - 顆粒球マクロファージコロニー刺激因子変異体 - Google Patents

顆粒球マクロファージコロニー刺激因子変異体 Download PDF

Info

Publication number
JP2023547883A
JP2023547883A JP2023525008A JP2023525008A JP2023547883A JP 2023547883 A JP2023547883 A JP 2023547883A JP 2023525008 A JP2023525008 A JP 2023525008A JP 2023525008 A JP2023525008 A JP 2023525008A JP 2023547883 A JP2023547883 A JP 2023547883A
Authority
JP
Japan
Prior art keywords
csf
cell
recombinant human
recombinant protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547883A5 (enExample
Inventor
フェルダウス，マイケル
ヨスト，ジェフリー
Original Assignee
パートナー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パートナー セラピューティクス インコーポレイテッド filed Critical パートナー セラピューティクス インコーポレイテッド
Publication of JP2023547883A publication Critical patent/JP2023547883A/ja
Publication of JP2023547883A5 publication Critical patent/JP2023547883A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023525008A 2020-10-26 2021-10-25 顆粒球マクロファージコロニー刺激因子変異体 Pending JP2023547883A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105425P 2020-10-26 2020-10-26
US63/105,425 2020-10-26
US202163177481P 2021-04-21 2021-04-21
US63/177,481 2021-04-21
PCT/US2021/056413 WO2022093671A1 (en) 2020-10-26 2021-10-25 Granulocyte macrophage-colony stimulating factor mutants

Publications (2)

Publication Number Publication Date
JP2023547883A true JP2023547883A (ja) 2023-11-14
JP2023547883A5 JP2023547883A5 (enExample) 2024-11-06

Family

ID=81383210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525008A Pending JP2023547883A (ja) 2020-10-26 2021-10-25 顆粒球マクロファージコロニー刺激因子変異体

Country Status (5)

Country Link
US (1) US20240182535A1 (enExample)
EP (1) EP4232067A4 (enExample)
JP (1) JP2023547883A (enExample)
CA (1) CA3196431A1 (enExample)
WO (1) WO2022093671A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301798A (ja) * 1987-01-29 1988-12-08 ザイモジェネティクス，インコーポレイティド コロニー刺激因子誘導体
JPH01502196A (ja) * 1987-02-06 1989-08-03 ジェネテイックス・インスティテュート・インコーポレイテッド 炭水化物含量を低下させたコロニー刺激因子
JPH02152995A (ja) * 1988-07-08 1990-06-12 Sumitomo Chem Co Ltd ヒト顆粒球・マクロファージコロニー刺激因子の分離精製法
JPH03502322A (ja) * 1987-10-30 1991-05-30 イミュネックス・コーポレーション ヒトコロニー形成刺激因子の非グリコシル化類似体
EP0646643A1 (en) * 1993-06-30 1995-04-05 Lucky Ltd. Modified human granulocyte macrophage-colony stimulating factor gene and expression thereof in yeast
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5032676A (en) * 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
US20080076706A1 (en) * 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
US9320777B2 (en) * 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301798A (ja) * 1987-01-29 1988-12-08 ザイモジェネティクス，インコーポレイティド コロニー刺激因子誘導体
JPH01502196A (ja) * 1987-02-06 1989-08-03 ジェネテイックス・インスティテュート・インコーポレイテッド 炭水化物含量を低下させたコロニー刺激因子
JPH03502322A (ja) * 1987-10-30 1991-05-30 イミュネックス・コーポレーション ヒトコロニー形成刺激因子の非グリコシル化類似体
JPH02152995A (ja) * 1988-07-08 1990-06-12 Sumitomo Chem Co Ltd ヒト顆粒球・マクロファージコロニー刺激因子の分離精製法
EP0646643A1 (en) * 1993-06-30 1995-04-05 Lucky Ltd. Modified human granulocyte macrophage-colony stimulating factor gene and expression thereof in yeast
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine (Registerd Trademark", PARTNER THERAPEUTICS WEBSITE, vol. [Retrived on 2025.09.11], JPN6025038586, 28 May 2020 (2020-05-28), ISSN: 0005868923 *

Also Published As

Publication number Publication date
US20240182535A1 (en) 2024-06-06
WO2022093671A9 (en) 2023-04-20
EP4232067A4 (en) 2024-10-23
WO2022093671A1 (en) 2022-05-05
CA3196431A1 (en) 2022-05-05
EP4232067A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
US9611307B2 (en) Method for increasing granulocyte number in a patient by administering superactive IL-33 fragments
JP2016539944A (ja) 新規ｓａｒｓ免疫原性組成物
CZ386392A3 (en) Alpha interferon
CN105209054A (zh) 使用白细胞介素-10治疗疾病和病症的方法
BG99246A (bg) Молекули на рекомбинантна дезоксирибонуклеинова киселина (днк), кодиращи ензими аминопептидаза,и приложението им за получаването на ваксини против хелминтни инфекции
KR19990063653A (ko) 케모킨 억제제
US20240139296A1 (en) Formulations of ace2 fc fusion proteins
JP3908165B2 (ja) 多発性硬化症の治療におけるケモカイン変異体
KR20240149406A (ko) 키메라 폴리펩티드
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN116323659A (zh) 融合多肽
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
CN116507355A (zh) 粒细胞巨噬细胞集落刺激因子突变体
WO2023094571A1 (en) Stabilization of ace2 fusion proteins
JP7857940B2 (ja) 顆粒球マクロファージコロニー刺激因子の製造
CN103044554A (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
KR101947342B1 (ko) Gm-csf 반감기를 증가시키는 방법
US20170073375A1 (en) Enhanced influenza hemagglutinin binders
CN116685598A (zh) 干扰素taufc-融合蛋白和治疗方法冠状病毒感染

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230713

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260526